03 Nov 2021
Posted in Pharma
Diagnosed prevalent cases of hemophilia A and B in China to increase by 2.51% by 2030, forecasts GlobalData
The diagnosed prevalent cases of hemophilia A and hemophilia B in China are expected to increase at an AGR of 2.51% between 2020 and 2030, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Hemophilia A and B: Epidemiology Forecast to 2030’, reveals that across the eight major markets (8MM*) combined is expected to increase from 0.07 million cases in 2020 to 0.08 million in 2030, at an annual growth rate (AGR) of 1.18%.
The report notes that the major drivers for the spike in the diagnosed prevalent cases of hemophilia A and hemophilia B in China is attributable to the huge population bases. The development of inhibitors of factor VIII and factor IX is an important complication of hemophilia A and hemophilia B, and the population with this complication in China is also large.
Rahul N Ravi, Epidemiologist at GlobalData, comments: “Hemophilia is a rare, genetic, potentially life-threatening bleeding disorder. It is estimated that about 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B. The introduction of universal guidelines for the screening and handling of blood and blood products has greatly reduced the number of hemophiliacs being newly infected with transfusion-transmitted infections like HIV and HCV. Both HIV and HCV are expected to impose a considerable burden as both diseases are expected to remain prevalent in the hemophiliac population in all the markets.”
*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and China.